IL239657B - Pharmaceutical preparations with improved bioavailability - Google Patents
Pharmaceutical preparations with improved bioavailabilityInfo
- Publication number
- IL239657B IL239657B IL239657A IL23965715A IL239657B IL 239657 B IL239657 B IL 239657B IL 239657 A IL239657 A IL 239657A IL 23965715 A IL23965715 A IL 23965715A IL 239657 B IL239657 B IL 239657B
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- improved bioavailability
- bioavailability
- improved
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361755074P | 2013-01-22 | 2013-01-22 | |
PCT/EP2014/050974 WO2014114575A1 (en) | 2013-01-22 | 2014-01-20 | Pharmaceutical composition with improved bioavailability |
Publications (2)
Publication Number | Publication Date |
---|---|
IL239657A0 IL239657A0 (en) | 2015-08-31 |
IL239657B true IL239657B (en) | 2019-05-30 |
Family
ID=50023547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL239657A IL239657B (en) | 2013-01-22 | 2015-06-25 | Pharmaceutical preparations with improved bioavailability |
Country Status (24)
Country | Link |
---|---|
US (2) | US9427427B2 (ru) |
EP (1) | EP2948141A1 (ru) |
JP (1) | JP6192244B2 (ru) |
KR (1) | KR101737250B1 (ru) |
CN (3) | CN104936589A (ru) |
AR (1) | AR094548A1 (ru) |
AU (1) | AU2014210103B2 (ru) |
BR (1) | BR112015015758B1 (ru) |
CA (1) | CA2892025C (ru) |
CL (1) | CL2015001649A1 (ru) |
CR (1) | CR20150287A (ru) |
EA (1) | EA028009B1 (ru) |
HK (1) | HK1211217A1 (ru) |
IL (1) | IL239657B (ru) |
MA (1) | MA38289A1 (ru) |
MX (1) | MX372668B (ru) |
MY (1) | MY192032A (ru) |
NZ (1) | NZ708272A (ru) |
PE (1) | PE20151335A1 (ru) |
PH (1) | PH12015501620B1 (ru) |
SG (1) | SG11201504499VA (ru) |
UA (1) | UA116004C2 (ru) |
WO (1) | WO2014114575A1 (ru) |
ZA (1) | ZA201504187B (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2016144187A (ru) * | 2014-04-15 | 2018-05-16 | Ф. Хоффманн-Ля Рош Аг | Твердые формы фармацевтически активного соединения |
PT107846B (pt) * | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
MA41108B1 (fr) * | 2014-12-05 | 2021-03-31 | Aragon Pharmaceuticals Inc | Compositions anticancéreuses |
WO2016090105A1 (en) | 2014-12-05 | 2016-06-09 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
EP3307246A1 (en) | 2015-06-09 | 2018-04-18 | Capsugel Belgium NV | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
KR20180118519A (ko) * | 2017-04-21 | 2018-10-31 | (주)바이오시네틱스 | 지질을 밀링 공정의 윤활제로 이용하는 활성물질 나노입자의 제조 방법 |
JP7190452B2 (ja) * | 2017-07-04 | 2022-12-15 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 医薬組成物及びその製造方法 |
CN111511365A (zh) * | 2017-11-10 | 2020-08-07 | 分散技术有限责任公司 | 改进的药物制剂 |
WO2019193488A1 (en) | 2018-04-06 | 2019-10-10 | Capsugel Belgium Nv | Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)] |
WO2019213106A1 (en) | 2018-04-30 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of idasanutlin |
TW202444718A (zh) * | 2019-01-25 | 2024-11-16 | 英屬開曼群島商百濟神州有限公司 | 作為b-raf激酶二聚體抑制劑之化合物及其製備方法 |
MX2021010906A (es) * | 2019-03-11 | 2021-10-01 | Ptc Therapeutics Inc | Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas. |
US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
EP3977997A4 (en) * | 2019-05-31 | 2022-07-27 | Jiangsu Hengrui Medicine Co., Ltd. | SOLID DISPERSION AND PROCESS FOR PRODUCTION |
AU2020353381A1 (en) | 2019-09-23 | 2022-04-07 | Bionomics Limited | Therapeutic formulations and uses thereof |
KR20220109430A (ko) * | 2019-12-02 | 2022-08-04 | 아스트라제네카 아베 | 6-(2-클로로-6-메틸피리딘-4-일)-5-(4-플루오로페닐)-1,2,4-트리아진-3-아민의 고체 약학 제형 |
BR112022011555A2 (pt) * | 2019-12-20 | 2022-08-30 | Intervet Int Bv | Composição farmacêutica de um composto pirazólico disperso em uma matriz polimérica |
WO2021248122A1 (en) * | 2020-06-05 | 2021-12-09 | Applied Materials, Inc. | Coated drug compositions and methods of preparing the same |
CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
CA3203975A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
CN117500923A (zh) | 2021-04-07 | 2024-02-02 | 巴特尔纪念研究院 | 用于鉴定和使用非病毒载体的快速设计、构建、测试和学习技术 |
EP4119128A1 (en) * | 2021-07-13 | 2023-01-18 | Dr. Falk Pharma Gmbh | Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion |
IL318192A (en) * | 2022-07-26 | 2025-03-01 | Pharma Cinq Llc | Amorphous formulation of uridine triacetate and its uses |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
GB9511220D0 (en) | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
BR9706897B1 (pt) | 1996-05-20 | 2010-09-21 | forma de dosagem farmacêutica. | |
SE9700655L (sv) | 1997-02-25 | 1998-05-11 | Neste Oy | Förfarande för framställning av ftalsyraanhydrid |
US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
AU775523B2 (en) | 1998-12-11 | 2004-08-05 | Pharmasolutions, Inc. | Self-emulsifying compositions for drugs poorly soluble in water |
ES2306646T3 (es) | 1999-02-09 | 2008-11-16 | Pfizer Products Inc. | Composiciones de farmacos basicos con biodisponibilidad incrementada. |
US6057289A (en) | 1999-04-30 | 2000-05-02 | Pharmasolutions, Inc. | Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system |
AU7105501A (en) | 2000-07-17 | 2002-01-30 | Yamanouchi Pharma Co Ltd | Pharmaceutical composition improved in peroral absorbability |
SK6572003A3 (en) | 2000-10-31 | 2003-10-07 | Boehringer Ingelheim Pharma | Oral self-emulsifying formulations of pyranone protease inhibitors |
JP2006500387A (ja) | 2002-08-15 | 2006-01-05 | 雲清 劉 | 固形ナノ医薬およびその調製方法 |
US7438261B2 (en) | 2004-09-09 | 2008-10-21 | David R. Porter | Stratospheric balloon utilizing electrostatic inflation of walls |
CN103272234A (zh) | 2006-03-20 | 2013-09-04 | 沃泰克斯药物股份有限公司 | 药物组合物 |
US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
NZ594398A (en) * | 2009-04-03 | 2014-03-28 | Plexxikon Inc | Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof |
CN102871950B (zh) * | 2011-07-15 | 2016-04-20 | 上海睿智化学研究有限公司 | 一种熊果酸固体分散体及其制备方法 |
US20130245089A1 (en) * | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
US20140128431A1 (en) * | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
-
2014
- 2014-01-20 CN CN201480005646.7A patent/CN104936589A/zh active Pending
- 2014-01-20 WO PCT/EP2014/050974 patent/WO2014114575A1/en active Application Filing
- 2014-01-20 PE PE2015001370A patent/PE20151335A1/es unknown
- 2014-01-20 EA EA201591276A patent/EA028009B1/ru not_active IP Right Cessation
- 2014-01-20 UA UAA201507997A patent/UA116004C2/uk unknown
- 2014-01-20 MX MX2015008911A patent/MX372668B/es active IP Right Grant
- 2014-01-20 CN CN202011052449.4A patent/CN112353762A/zh active Pending
- 2014-01-20 CA CA2892025A patent/CA2892025C/en active Active
- 2014-01-20 JP JP2015553108A patent/JP6192244B2/ja active Active
- 2014-01-20 BR BR112015015758-0A patent/BR112015015758B1/pt active IP Right Grant
- 2014-01-20 EP EP14701504.4A patent/EP2948141A1/en active Pending
- 2014-01-20 NZ NZ708272A patent/NZ708272A/en not_active IP Right Cessation
- 2014-01-20 SG SG11201504499VA patent/SG11201504499VA/en unknown
- 2014-01-20 MY MYPI2015702350A patent/MY192032A/en unknown
- 2014-01-20 CN CN202011052471.9A patent/CN112370427A/zh active Pending
- 2014-01-20 AU AU2014210103A patent/AU2014210103B2/en active Active
- 2014-01-20 KR KR1020157019822A patent/KR101737250B1/ko active Active
- 2014-01-21 US US14/159,679 patent/US9427427B2/en active Active
- 2014-01-22 AR ARP140100191A patent/AR094548A1/es unknown
-
2015
- 2015-05-28 CR CR20150287A patent/CR20150287A/es unknown
- 2015-06-10 ZA ZA2015/04187A patent/ZA201504187B/en unknown
- 2015-06-12 CL CL2015001649A patent/CL2015001649A1/es unknown
- 2015-06-25 IL IL239657A patent/IL239657B/en active IP Right Grant
- 2015-07-22 PH PH12015501620A patent/PH12015501620B1/en unknown
- 2015-07-23 MA MA38289A patent/MA38289A1/fr unknown
- 2015-12-08 HK HK15112066.7A patent/HK1211217A1/xx unknown
-
2016
- 2016-07-01 US US15/200,419 patent/US10034854B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211217A1 (en) | Pharmaceutical composition with improved bioavailability | |
RS59756B1 (sr) | Kombinovana farmaceutska kompozicija | |
HK1219663A1 (zh) | 藥物組合 | |
GB201322602D0 (en) | Pharmaceutical compounds | |
GB201306610D0 (en) | Pharmaceutical compounds | |
ZA201602047B (en) | Pharmaceutical compounds | |
SG11201601477VA (en) | Pharmaceutical composition | |
ZA201600027B (en) | Pharmaceutical preparation | |
GB201312386D0 (en) | Pharmaceutical compounds | |
HUP1300496A2 (hu) | Stabil kombinációs gyógyszerkészítmény | |
HK1220143A1 (zh) | 藥物組合物 | |
IL244316A0 (en) | A new composition of a drug | |
ZA201506465B (en) | Pharmaceutical preparation | |
GB201317166D0 (en) | Pharmaceutical compounds | |
GB201316791D0 (en) | Pharmaceutical Compounds | |
GB201316780D0 (en) | Pharmaceutical compounds | |
GB201315734D0 (en) | Pharmaceutical compounds | |
GB201315733D0 (en) | Pharmaceutical compounds | |
GB201312464D0 (en) | Pharmaceutical compounds | |
GB201304625D0 (en) | New pharmaceutical composition | |
GB201308781D0 (en) | Pharmaceutical compounds | |
GB201308782D0 (en) | Pharmaceutical compounds | |
GB201308780D0 (en) | Pharmaceutical compounds | |
GB201321316D0 (en) | Pharmaceutical Compound | |
GB201309405D0 (en) | Pharmaceutical compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |